Pharmacokinetics of Nevirapine in HIV and Tuberculosis-coinfected Children Receiving Antiretroviral Fixed-dose Combination Tablets While Receiving Rifampicin-containing Tuberculosis Treatment and After Rifampicin Discontinuation

被引：6

作者：

Prasitsuebsai, Wasana

Cressey, Tim R. ^{[2
,3
]}

Capparelli, Edmund ^{[4
]}

Vanprapar, Nirun

Lapphra, Keswadee

Chokephaibulkit, Kulkanya ^{[1
]}

机构：

[1] Mahidol Univ, Siriraj Hosp, Div Infect Dis, Dept Pediat,Fac Med, Bangkok 10700, Thailand

[2] Chiang Mai Univ, Program HIV Prevent & Treatment IRD URI 174, Dept Med Technol, Fac Associated Med Sci, Chiang Mai 50000, Thailand

[3] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA

[4] Univ Calif San Diego, Dept Pediat Pharm & Drug Discovery, San Diego, CA 92103 USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2012年 / 31卷 / 04期

关键词：

HIV/TB coinfection; nevirapine; rifampicin; children; PLASMA-CONCENTRATIONS;

D O I：

10.1097/INF.0b013e3182401c41

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation. The median age (range) was 9.7 (4.4-11.7) years. The nevirapine area under the concentration versus time curve from 0 to 12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mu g.h/mL and 6.4 (3.00-13.27) mu g/mL, respectively, providing adequate exposure.

引用

页码：389 / 391

页数：3

共 10 条

[1] Barlow-Mosha L, 2009, 16 C RETR OPP INF MO
[2] Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children
Chokephaibulkit, Kulkanya
Cressey, Tim R.
Capparelli, Edmund
Sirisanthana, Virat
Muresan, Petronella
Hongsiriwon, Suchat
Ngampiyaskul, Chaiwat
Limwongse, Chanin
Wittawatmongkol, Orasri
Aurpibul, Linda
Kabat, Bill
Toye, MariPat
Smith, Mary Elizabeth
Eksaengsri, Achara
McIntosh, Kenneth
Yogev, Ram
[J]. ANTIVIRAL THERAPY, 2011, 16 (08) : 1287 - 1295
[3] Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis
Cohen, Karen
van Cutsem, Gilles
Boulle, Andrew
McIlleron, Helen
Goemaere, Eric
Smith, Peter J.
Maartens, Gary
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) : 389 - 393
[4] Nevirapine plasma exposure affects both durability of viral suppression and selection of Nevirapine primary resistance mutations in a clinical setting
de Requena, DG
Bonora, S
Garazzino, S
Sciandra, M
D'Avolio, A
Raiteri, R
Marrone, R
Boffito, M
De Rosa, FG
Sinicco, A
Di Perri, G
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3966 - 3969
[5] Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography
Droste, JAH
Verweij-van Wissen, CPWGM
Burger, DM
[J]. THERAPEUTIC DRUG MONITORING, 2003, 25 (03) : 393 - 399
[6] Childhood TB epidemiology and treatment outcomes in Thailand: a TB active surveillance network, 2004 to 2006
Lolekha, Rangsima
Anuwatnonthakate, Amornrat
Nateniyom, Sriprapa
Sumnapun, Surin
Yamada, Norio
Wattanaamornkiat, Wanpen
Sattayawuthipong, Wanchai
Charusuntonsri, Pricha
Sanguanwongse, Natpatou
Wells, Charles D.
Varma, Jay K.
[J]. BMC INFECTIOUS DISEASES, 2008, 8 (1)
[7] Reversible Reduction of Nevirapine Plasma Concentrations During Rifampicin Treatment in Patients Coinfected With HIV-1 and Tuberculosis
Matteelli, Alberto
Saleri, Nuccia
Villani, Paola
Bonkoungou, Victor
Carvalho, Anna Cristina C.
Kouanda, Seni
Sanou, Marie J.
Simpore, Jacques
Monno, Laura
Carosi, Giampiero
Regazzi, Mario
Dembele, Mathurin
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 (01) : 64 - 69
[8] Oudijk JM, 2010, 5 IAS C PATH TREATM
[9] Shah I, 2011, INDIAN PEDIAT
[10] WHO, ANT THER HIV INF INF

← 1 →